Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $20.50 Consensus Price Target from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received an average recommendation of “Hold” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $20.50.

Several equities research analysts have recently issued reports on KROS shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Leerink Partners dropped their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday. Zacks Research downgraded Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday.

Keros Therapeutics Stock Performance

KROS opened at $10.10 on Monday. The stock has a market capitalization of $200.28 million, a price-to-earnings ratio of -2.73 and a beta of 0.99. The company has a fifty day moving average of $10.63 and a 200 day moving average of $12.05. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, equities research analysts forecast that Keros Therapeutics will post -5.16 earnings per share for the current year.

Insider Activity at Keros Therapeutics

In related news, Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the transaction, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,702.24. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the completion of the sale, the director owned 10,958 shares in the company, valued at $117,579.34. This represents a 19.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,425 shares of company stock valued at $89,994. 12.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in Keros Therapeutics during the second quarter worth approximately $29,898,000. Renaissance Technologies LLC raised its position in Keros Therapeutics by 282.5% during the fourth quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock valued at $12,047,000 after purchasing an additional 436,986 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Keros Therapeutics in the 2nd quarter valued at approximately $4,251,000. Caption Management LLC lifted its stake in shares of Keros Therapeutics by 114.1% in the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after purchasing an additional 291,997 shares during the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in shares of Keros Therapeutics by 683.7% in the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after purchasing an additional 264,445 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.